Given that patients with a PIK3CA mutation in the tumor might have more benefit from PI3K inhibition [24, 25, 47], and, according to our data, could have more tumor-associated CD8, a combination treatment with immune checkpoint blockade plus PI3K inhibition deserves exploration in a clinical trial. This evidence concerns the gene CD8A and neoplasm.